SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as chatter increases around its role as a data provider, especially for Kalshi and its adoption. The community is speculating on potential integrations with major players and anticipating significant price movements. Some users highlight its utility and real-world asset (RWA) status as key drivers for future growth.

EVAA Protocol

EVAA Protocol ($EVAA) is trending as community members discuss recent upward price movement, with some calling for a continued run. Others point to the token being at a potential bottom after not participating in previous cycles. Recent short positions and TA analysis are also being heavily discussed.

DTE Energy Co. operates as a diversified energy company, which engages in the development and management of energy-related businesses and services. It operates through the following segments: Electric, Gas, DTE Vantage, Energy Trading, and Corporate and Other. The Electric segment consists of generation, purchase, distribution, and sale of electricity to residential, commercial, and industrial customers in southeastern Michigan. The Gas segment is involved in the purchase, storage, transportation, distribution, and sale of natural gas to residential, commercial, and industrial customers throughout Michigan, and the sale of storage and transportation capacity. The DTE Vantage segment focuses on projects that deliver energy and utility-type products and services to industrial, commercial, and institutional customers, produce reduced emissions fuel, and sell electricity and pipeline-quality gas from renewable energy projects. The Energy Trading segment covers energy marketing and trading operations. The Corporate and Other segment includes various holding company activities, holds certain non-utility debt, and holds certain investments, as well as funds supporting regional development and economic growth. The company was founded in January 1995 and is headquartered in Detroit, MI.

DTE Energy Co.

DTE Energy is trending amid discussions around earnings, investments in clean energy, and infrastructure upgrades. Community members are weighing the company's growth prospects against its debt and the impact of regulatory changes. Recent analyst ratings and price target adjustments are also contributing to the conversation.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: Frito-Lay North America (FLNA), Quaker Foods North America (QFNA), PepsiCo Beverages North America (PBNA), Latin America (LatAm), Europe, Africa, Middle East, and South Asia (AMESA), and Asia Pacific, Australia and New Zealand, and China Region (APAC). The FLNA segment consists of branded convenient food businesses in the United States and Canada. The QFNA segment includes cereals, rice, and pasta under the Quaker, Pearl Milling Company, Quaker Chewy, Cap'n Crunch, Life, and Rice-A-Roni brands. The PBNA segment is composed of beverage concentrates, fountain syrups, and finished goods under various beverage brands such as Pepsi, Gatorade, Mountain Dew, Diet Pepsi, Aquafina, Diet Mountain Dew, Sierra Mist, and Mug. The LatAm segment covers beverage, food, and snack businesses in the Latin American region. The Europe segment offers beverage, food, and snack goods in Europe and Sub-Saharan Africa regions. The AMESA segment deals with all beverage and convenient food businesses in Africa, the Middle East, and South Asia. The APAC segment refers to all business operations in the Asia Pacific, Australia and New Zealand, and China region. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is trending as discussions emerge around activist investor Elliott Investment Management building a significant stake and potentially pushing for strategic changes to boost shareholder value, similar to Coca-Cola's approach. Community members are speculating on the potential impact of this development, including restructuring and a renewed focus on growth, while considering PEP's performance in relation to competitors and its attractiveness as a defensive stock.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita (DVA) is trending as discussions revolve around reimbursement clarity and the potential impact of extending TDAPA (Transitional Drug Add-on Payment Adjustment). The community is focused on whether DaVita will adopt DefenCath, a product proven to reduce catheter-related bloodstream infections, with some suggesting its non-use raises questions about patient safety and cost control.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending amid buyout speculation and positive sentiment around its MASH drug, Rezdiffra, especially following strong Q3 revenue despite wider-than-expected EPS loss. The community is actively discussing potential buyout prices and the company's strategic position in the MASH market, particularly as a potential combination therapy with GLP-1 agonists. Additionally, Madrigal's European launch of Rezdiffra is being closely watched as a key growth driver.

Direxion Shares ETF Trust - Direxion Daily AAPL Bull 2X Shares

Direxion Daily AAPL Bull 1.5X Shares

Direxion Daily AAPL Bull 1.5X Shares ($AAPU) is trending as traders discuss potential upside for Apple and the broader market, with some noting technical indicators and potential catalysts like a new iPhone release. Community members are actively trading AAPU, looking for quick gains and swing opportunities, while also considering long-term positions in anticipation of future growth. Some traders are monitoring unusual options activity and considering strategies involving AAPU calls and puts.

Direxion Shares ETF Trust - Direxion Daily 20+ Year Treasury Bear -3X Shares

Direxion Daily 20+ Year Treasury Bear 3X Shares

TMV is trending as bond yields rise, driven by concerns over persistent inflation and the Federal Reserve's commitment to maintaining elevated interest rates. The community is actively discussing potential entry and exit points, analyzing technical indicators, and weighing the impact of economic data releases on bond prices. Traders are also exploring hedging strategies using TMV amidst market uncertainty.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insmed Inc

Insmed ($INSM) is trending as discussions revolve around its potential for growth, fueled by strong Brinsupri uptake and promising pipeline developments. The community highlights analysts' increased price targets and comparisons to blockbuster drugs like Humira, with many anticipating pivotal data releases and label expansions. However, some caution against the high valuation and potential risks associated with pharmaceutical stocks.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending amidst political and economic discussions, including government shutdowns, fiscal policy, and trade relations. Community members are weighing in on diverse topics, from the performance of analysis to geopolitical events and their potential market impact. Broader concerns include inflation, job market data, and the influence of political actions on economic stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Y Intercept Hong Kong Ltd Takes $475,000 Position in Trevi Therapeutics, Inc. $TRVI

Y Intercept Hong Kong Ltd acquired a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities...

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a...

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference PR Newswire NEW HAVEN, Conn., Nov. 4, 2025 Fireside Chat...

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's  What You Should Know

The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough Trevi Therapeutics Completes Enrollment for Phase 2b CORAL...

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Trevi Therapeutics to Participate in Upcoming February Investor Conferences Trevi Therapeutics to Participate in Upcoming February Investor Conferences PR Newswire NEW HAVEN, Conn., Jan. 30, 2025 NEW...

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference Trevi Therapeutics Announces Company...

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering PR Newswire NEW HAVEN, Conn., Dec. 16, 2024 NEW...

Shares of Trevi Therapeutics Inc. rose over 6% on Friday morning, building on momentum from the previous session when the stock hit over two-year intraday highs.&nbsp;The surge came as heavy retail buzz pushed the ticker to prominence on Stocktwits, where message volume spiked over 4,900% on Thursday.The company announced that its phase 2b study of Haduvio, an investigational therapy for idiopathic pulmonary fibrosis (IPF) with chronic cough, has achieved 75% of its enrollment target of 160 patients.&nbsp;An independent statistician confirmed the sample size following a re-estimation analysis, ensuring the trial’s design remains statistically robust.&nbsp;The analysis involved treating 80 patients with Haduvio’s highest dose (108 mg twice daily) over six weeks.Trevi reiterated that topline results are expected in the first half of 2025.Wall Street analysts responded positively to the update:•&nbsp;Jones Research reiterated a ‘Buy’ rating, stating the analysis enhances confidence in the trial’s statistical assumptions, which indicate a high likelihood of demonstrating significant cough reduction.• Needham’s Serge Belanger called the result the “best case outcome,” highlighting it as a de-risking event.&nbsp;He highlighted that&nbsp;the study’s treatment effect size and dropout rates align with initial assumptions, supporting the original design. Needham maintained a ‘Buy’ rating with an $8 price target.• H.C. Wainwright raised its price target to $7.50 from $6, describing the update as a “material positive” for investor sentiment ahead of data readouts.Year-to-date, TRVI stock has gained over 170%, as of the last close,&nbsp; showcasing strong investor interest in the company’s pipeline and prospects.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%

An independent statistician confirmed the sample size following a re-estimation analysis, ensuring that the trial’s design remains statistically robust.

Equity

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Trevi Therapeutics Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$10.80
Prev Close	$11.01
Open	$11.00
Dividend Yield	0.00%
50-Day Moving Average	$9.45
Beta	0.64
Avg. Volume	1.59M
PE Ratio	-26.17

52-Week High	$11.83
52-Week Low	$2.36
Market Capitalization	$1.34B
EPS (Annual)	-$0.4698
Price to Book	6.75
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TRVI
Trevi Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRVI News

TRVITrevi Therapeutics Inc